Protective effects of resveratrol and SR1001 on hypoxia-induced pulmonary hypertension in rats

References

• Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–50.
   PubMed Web of Science ®Google Scholar
• Perrin S, Chaumais MC, O’Connell C, Amar D, Savale L, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O, et al. New pharmacotherapy options for pulmonary arterial hypertension. Expert Opin Pharmacother. 2015;16(14):2113–31. doi:10.1517/14656566.2015.1074177.
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017.
   PubMed Web of Science ®Google Scholar
• Burks M, Stickel S, Galiè N.Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs. 2018;18(4):249–57. doi:10.1007/s40256-018-0272-5.
   PubMed Web of Science ®Google Scholar
• Yu L, Quinn DA, Garg HG, Hales CA. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res. 2005;97(9):937–45. doi:10.1161/01.RES.0000188211.83193.1a.
   PubMed Web of Science ®Google Scholar
• Amaya CN, Mitchell DC, Bryan BA.Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth. BMC Cancer. 2017;17(1):485. doi:10.1186/s12885-017-3470-7.
   PubMedGoogle Scholar
• Do EZ, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J. 2009;73(9):1731–39. doi:10.1253/circj.CJ-09-0135.
   PubMed Web of Science ®Google Scholar
• Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guérin P, Sagan C, Pacaud P, Loirand G. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol. 2005;146(7):1010–18. doi:10.1038/sj.bjp.0706408.
   PubMed Web of Science ®Google Scholar
• Maston LD, Jones DT, Giermakowska W, Howard TA, Cannon JL, Wang W, Wei Y, Xuan W, Resta TC, Gonzalez Bosc LV, et al. Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L609–L624. doi:10.1152/ajplung.00531.2016.
   PubMed Web of Science ®Google Scholar
• Wang J, Weigand L, Lu W, Sylvester JT, L. Semenza G, Shimoda LA. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res. 2006;98(12):1528–37. doi:10.1161/01.RES.0000227551.68124.98.
   PubMed Web of Science ®Google Scholar
• Bakheet SA, Alzahrani MZ, Ansari MA, Nadeem A, Zoheir KMA, Attia SM, AL-Ayadhi LY, Ahmad SF. Resveratrol ameliorates dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in a BTBR T + tf/J mouse model of Autism. Mol Neurobiol. 2017;54(7):5201–12. doi:10.1007/s12035-016-0066-1.
   PubMed Web of Science ®Google Scholar
• Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6(2):E38. doi:10.3390/diseases6020038.
   PubMedGoogle Scholar
• Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen H-R, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011;146(5):772–84. doi:10.1016/j.cell.2011.07.033.
   PubMed Web of Science ®Google Scholar
• Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, et al. Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci USA. 2015;112(20):E2677–86. doi:10.1073/pnas.1424774112.
   PubMed Web of Science ®Google Scholar
• Petro TM.Regulatory role of resveratrol on Th17 in autoimmune disease. Int Immunopharmacol. 2011;11(3):310–18. doi:10.1016/j.intimp.2010.07.011.
   PubMed Web of Science ®Google Scholar
• Weng BB, Lin WS, Chang JC, Chiou RY. The phytogestrogenic stilbenes, arachidin-1 and resveratrol, modulate regulatory T cell functions responsible for successful aging in aged ICR mice. Int J Mol Med. 2016;38(6):1895–904. doi:10.3892/ijmm.2016.2792.
   PubMed Web of Science ®Google Scholar
• Pannu N, Bhatnagar A. Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. Biomed Pharmacother. 2019;109:2237–51. doi:10.1016/j.biopha.2018.11.075.
   PubMed Web of Science ®Google Scholar
• Koushki M, Amiri-Dashatan N, Ahmadi N, Abbaszadeh HA, Rezaei-Tavirani M. Resveratrol: A miraculous natural compound for diseases treatment. Food Sci Nutr. 2018;6(8):2473–90. doi:10.1002/fsn3.855.
   PubMed Web of Science ®Google Scholar
• Wang D, Li SP, Fu JS, Zhang S, Bai L, Guo L. Resveratrol defends blood-brain barrier integrity in experimental autoimmune encephalomyelitis mice. J Neurophysiol. 2016;116(5):2173–79. doi:10.1152/jn.00510.2016.
   PubMed Web of Science ®Google Scholar
• Li C, Liu PP, Tang DD, Song R, Zhang YQ, Lei S, Wu SJ. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension. Pulm Pharmacol Ther. 2018;50:111–22.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shan J, Chen X, Li S, Long D, Li Y. Celastrol mediates Th17 and Treg cell generation via metabolic signaling. Biochem Biophys Res Commun. 2018;497(3):883–89. doi:10.1016/j.bbrc.2018.02.163.
   PubMed Web of Science ®Google Scholar
• Lopez NC, Ebensperger G, Herrera EA, Reyes RV, Calaf G, Cabello G, Moraga FA, Beñaldo FA, Diaz M, Parer JT, et al. Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs. Am J Physiol Regul Integr Comp Physiol. 2016;310(11):R1053–63. doi:10.1152/ajpregu.00177.2015.
   PubMed Web of Science ®Google Scholar
• Duong-Quy S, Bei Y, Liu Z, Dinh-Xuan AT.Role of Rho-kinase and its inhibitors in pulmonary hypertension. Pharmacol Ther. 2013;137(3):352–64. doi:10.1016/j.pharmthera.2012.12.003.
   PubMed Web of Science ®Google Scholar
• Aijaz S, D'Atri F, Citi S, Balda MS, Matter K. Binding of GEF-H1 to the tight junction-associated adaptor cingulin results in inhibition of Rho signaling and G1/S phase transition. Dev Cell. 2005;8(5):777–86. doi:10.1016/j.devcel.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Birukova AA, Adyshev D, Gorshkov B, Bokoch GM, Birukov KG, Verin AD. GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L540–8. doi:10.1152/ajplung.00259.2005.
   PubMed Web of Science ®Google Scholar
• Mizuarai S, Yamanaka K, Kotani H.Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006;66(12):6319–26. doi:10.1158/0008-5472.CAN-05-4629.
   PubMed Web of Science ®Google Scholar
• Zenke FT, Krendel M, DerMardirossian C, King CC, Bohl BP, Bokoch GM. p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor. J Biol Chem. 2004;279(18):18392–400. doi:10.1074/jbc.M400084200.
   PubMed Web of Science ®Google Scholar
• Nalli AD, Rajagopal S, Mahavadi S, Grider JR, Murthy KS. Inhibition of RhoA-dependent pathway and contraction by endogenous hydrogen sulfide in rabbit gastric smooth muscle cells. Am J Physiol Cell Physiol. 2015;308(6):C485–95. doi:10.1152/ajpcell.00280.2014.
   PubMed Web of Science ®Google Scholar
• Cao X, Luo T, Luo X, Tang Z. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens Res. 2014;37(9):803–10. doi:10.1038/hr.2014.90.
   PubMed Web of Science ®Google Scholar
• Prins KW, Thenappan T.World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34(3):363–74. doi:10.1016/j.ccl.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. doi:10.1056/NEJMoa1213917.
   PubMed Web of Science ®Google Scholar
• Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery J-L, Grünig E, et al. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44. doi:10.1056/NEJMoa1413687.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, Bouvaist H, Dauphin C, Picard F, Bulifon S, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691–97. doi:10.1183/09031936.00116313.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24(6):1007–10. doi:10.1183/09031936.04.00051104.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Kardiol Pol. 2015;73(12):1127–206. doi:10.5603/KP.2015.0242.
   PubMedGoogle Scholar
• Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Ikeda S, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol. 2013;33(12):2780–91. doi:10.1161/ATVBAHA.113.301357.
   PubMed Web of Science ®Google Scholar